Edwards Lifesciences sees FY26 adjusted EPS $2.80-$2.95, consensus $2.86

Sees FY26 revenue $6.4B-$6.8B, consensus $6.03B. Sees FY26 tax rate 16%-19%. “As we enter 2026, we are poised for sustainable growth and long-term value creation,” said Bernard Zovighian, Edwards’ CEO. “For the more than 20 million structural heart patients worldwide, we are continuing to bring novel and differentiated innovations and world-class evidence to transform care. In addition, we are excited to pioneer therapies for the many structural heart patient groups currently unaddressed today, such as those with asymptomatic AS and those with mitral, tricuspid or aortic regurgitation in need of a transcatheter replacement. Edwards is the only company committed to delivering first-of-its-kind innovations for all of these patients, leveraging our 65 years of leadership and valve expertise. This approach underscores our unwavering commitment to creating long-term value for patients, physicians, health systems and shareholders.”